-
Executive, ADL, and Cholinergic Functions in PD
… of balance. Patients with Parkinson's disease also suffer from non-motor symptoms, such as mental, memory, or mood … by mental and memory problems. Recent research from Dr. Bohnen's group at the University of Pittsburgh has …
-
Cannabinoid CB2 Receptors as a New Target for the Treatment of Disease Progression in Parkinson's Disease: Studies in LRRK2-Transgenic Pre-clinical Models
… as an anti-inflammatory and neuroprotective target: (i) from other neurodegenerative disorders to PD, and (ii) from neurotoxin-based models of this disorder to progressive …
-
Exenatide as a Treatment for Patients with Parkinson’s Disease
… Objective/Rationale: Laboratory data from several teams have indicated potential beneficial … in this field. Anticipated Outcome: The results from this project will provide high-quality data necessary …
-
Novel Enzymatic Method for Improving Therapeutic Targeting of Dopaminergic Afferents
… of dopaminergic afferents (nerves that conduct impulses from the peripheral body to the brain or spinal cord) from the substantia nigra . By removing PNNs, we anticipate …
-
Is Mitochondrial Hemoglobin Reduced in Parkinson’s Disease Brain?
… We are able to obtain these fully consented tissues from local and other UK brain banks operating under the … are related to disease. This work will form a springboard from which we can ask more specific questions about changes …
-
LRRK2 Phosphatases Confirmation
… This grant builds upon the research from a prior grant: Identification of the LRRK2 Phosphatase … and removing phosphates (by enzymes called phosphatases) from LRRK2. For instance, several LRRK2 disease mutants …